Zobrazeno 1 - 10
of 1 009
pro vyhledávání: '"T, Curiel"'
Autor:
Whitney C. Weber, Takeshi F. Andoh, Craig N. Kreklywich, Zachary J. Streblow, Michael Denton, Magdalene M. Streblow, John M. Powers, Gauthami Sulgey, Samuel Medica, Igor Dmitriev, David T. Curiel, Nicole N. Haese, Daniel N. Streblow
Publikováno v:
Vaccines, Vol 12, Iss 9, p 970 (2024)
Chikungunya virus (CHIKV) is a pathogenic arthritogenic alphavirus responsible for large-scale human epidemics for which a vaccine was recently approved for use. Mayaro virus (MAYV) is a related emerging alphavirus with epidemic potential with circul
Externí odkaz:
https://doaj.org/article/a5c3ecbf3e444fc38d200d6716b2545d
Autor:
Chandramani Singh, Savita Verma, Prabhakar Reddy, Michael S. Diamond, David T. Curiel, Chintan Patel, Manish Kumar Jain, Sagar Vivek Redkar, Amit Suresh Bhate, Vivek Gundappa, Rambabu Konatham, Leelabati Toppo, Aniket Chandrakant Joshi, Jitendra Singh Kushwaha, Ajit Pratap Singh, Shilpa Bawankule, Raches Ella, Sai Prasad, Brunda Ganneru, Siddharth Reddy Chiteti, Sreenivas Kataram, Krishna Mohan Vadrevu
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-9 (2023)
Abstract One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike intramuscular vaccines, intranasal COVID-19 vaccines may
Externí odkaz:
https://doaj.org/article/942566a9fd284c139cb86bb0528dbc2a
Autor:
Kexin Geng, Paul J. Rice-Boucher, Elena A. Kashentseva, Igor P. Dmitriev, Zhi Hong Lu, S. Peter Goedegebuure, William E. Gillanders, David T. Curiel
Publikováno v:
Viruses, Vol 15, Iss 11, p 2277 (2023)
mRNA vaccines have attracted widespread research attention with clear advantages in terms of molecular flexibility, rapid development, and potential for personalization. However, current mRNA vaccine platforms have not been optimized for induction of
Externí odkaz:
https://doaj.org/article/f5cd8059bf8f48c1a2dd7fc84922e25f
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-14 (2021)
Abstract Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecula
Externí odkaz:
https://doaj.org/article/2884d62b3ff9428ba246fbb13c87a66c
Autor:
Pérez, J. Pumares, González, M. Mateos, López, C. Rodríguez, García, T. Curiel, Pose, V. Varela
Publikováno v:
In Medicine - Programa de Formación Médica Continuada acreditado March 2021 13(27):1533-1537
Autor:
López, C. Rodríguez, García, T. Curiel, Pérez, J. Pumares, González, M. Mateos, Pose, V. Varela
Publikováno v:
In Medicine - Programa de Formación Médica Continuada acreditado March 2021 13(27):1493-1505
Autor:
Myungeun Lee, Paul J. Rice-Boucher, Logan Thrasher Collins, Ernst Wagner, Lorenzo Aulisa, Jeffrey Hughes, David T. Curiel
Publikováno v:
Viruses, Vol 14, Iss 10, p 2169 (2022)
Molecular therapies exploiting mRNA vectors embody enormous potential, as evidenced by the utility of this technology for the context of the COVID-19 pandemic. Nonetheless, broad implementation of these promising strategies has been restricted by the
Externí odkaz:
https://doaj.org/article/10047deae23a454ab209be6c271d1f07
Autor:
Ahmed O. Hassan, Swathi Shrihari, Matthew J. Gorman, Baoling Ying, Dansu Yaun, Saravanan Raju, Rita E. Chen, Igor P. Dmitriev, Elena Kashentseva, Lucas J. Adams, Colin Mann, Meredith E. Davis-Gardner, Mehul S. Suthar, Pei-Yong Shi, Erica Ollmann Saphire, Daved H. Fremont, David T. Curiel, Galit Alter, Michael S. Diamond
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109452- (2021)
Summary: SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-
Externí odkaz:
https://doaj.org/article/6b5e421c8ddd48718952e62139e47b88
Autor:
Rachael Mooney, Asma Abdul Majid, Jennifer Batalla-Covello, Diana Machado, Xueli Liu, Joanna Gonzaga, Revathiswari Tirughana, Mohamed Hammad, Maciej S. Lesniak, David T. Curiel, Karen S. Aboody
Publikováno v:
Molecular Therapy: Oncolytics, Vol 12, Iss , Pp 79-92 (2019)
Oncolytic virotherapy is a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the clinic has been hampered by rapid immune-mediated clearance or neutralization of the virus, which re
Externí odkaz:
https://doaj.org/article/640fdbac5c2342d1857ec93f5bfc628b
Autor:
Rebeca González-Pastor, Ahmad Mohammad Ashshi, Adel Galal El-Shemi, Igor P. Dmitriev, Elena A. Kashentseva, Zhi Hong Lu, S. Peter Goedegebuure, Osvaldo L. Podhajcer, David T. Curiel
Publikováno v:
Journal of Ovarian Research, Vol 12, Iss 1, Pp 1-10 (2019)
Abstract Background Virotherapy represents a promising approach for ovarian cancer. In this regard, conditionally replicative adenovirus (CRAd) has been translated to the context of human clinical trials. Advanced design of CRAds has sought to exploi
Externí odkaz:
https://doaj.org/article/7c2b01e7eb2848b08117b81f96e23ec9